Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience

Lorlatinib is the only targeted therapy approved in Canada to treat patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) whose tumor has progressed despite treatment with second-generation ALK tyrosine kinase inhibitor (TKI), a patient population with high unmet...

Descripción completa

Detalles Bibliográficos
Autores principales: Rupp, Martin, Fanton-Aita, Fiorella, Snow, Stephanie, Wheatley-Price, Paul, Melosky, Barbara, Juergens, Rosalyn A., Chu, Quincy, Blais, Normand, Banerji, Shantanu, Ng, Ryan, Khoudigian, Shoghag, Sharma, Arushi, On, Phu Vinh, Liu, Geoffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377946/
https://www.ncbi.nlm.nih.gov/pubmed/37504341
http://dx.doi.org/10.3390/curroncol30070481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377946/
https://www.ncbi.nlm.nih.gov/pubmed/37504341
http://dx.doi.org/10.3390/curroncol30070481

Ejemplares similares